Pharma Stocks

Multiple growth triggers ahead for Aurobindo Pharma as outlook stays strong

Respiratory launches, CDMO expansion and strong US and European businesses are key growth drivers; the stock trades at just under 16 times estimated FY28 earnings

Biocon spurts 3% as Pertuzumab drug moves closer to marketing nod in Europe

Biocon jumped nearly 3% in Monday's trade after the company's Pertuzumab biosimilar drug received EMA CHMP recommendation for breast cancer care.

Morepen Labs rises 7% to 52-week high; what moved this multibagger stock?

The gains in Morepen Labs come on the back of a positive business development announced by the company today involving the first phase of its manufacturing capacity expansion program.

Gland Pharma rallies 12%, stock hits 4-year high post Q1 results

Gland Pharma Share: The market price of Gland Pharma hit a high of ₹2,989.2 in intra-day deals on Tuesday. The stock bounced back 90 per cent from its 52-week low of ₹1,575 touched on March 16, 2026.

Laurus joins ₹1 trillion market cap club as stock zooms 120% in 1 year

In the past month, Laurus Labs outperformed the market by surging 22 per cent, as compared to 2.1 per cent rise in the Nifty Midcap 50 index.

Sun Pharma Q1 preview: Robust domestic growth to drive revenue by 11% Y-o-Y

Brokerages see an 11 per cent topline growth in Q1 FY27. HDFC Securities said that the US generic business will be muted due to the absence of gRevlimid, while the India business may grow 13 per cent.

Laurus Labs stock jumps 2%, hits new high on 125% surge in Q1 profit

Laurus Labs on Friday reported a 124.7% YoY surge in Q1 consolidated net profit at ₹361.99 crore, backed by 28.8% growth in total income. The stock has nearly doubled in the last one year.

Dr Reddy's Labs shares tank 9% to 52-week low after Q1 show. Time to sell?

Brokerages largely remain bearish on Dr Reddy's Labs shares following the Q1 earnings show.

Trump's 200% tariffs on imported generic medicines to test India's edge

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

Divi's Labs rallies 3%, market cap nears ₹2 trillion; what's driving stock?

As the largest pure-play API/CDMO, Divi's should continue benefiting from custom-synthesis order-book conversion and the structural China+1/BIOSECURE-linked tailwind, analysts believe.

Dr Reddy's drops 4% on semaglutide setback; should investors buy the dip?

The company said certain batches of semaglutide were found to be out of specification due to issues associated with the API used in the product

Glenmark Pharma jumps over 2% on launch of Olanzapine single-dose vial

Glenmark Pharma stock advanced over 2% in Monday's intra-day trade, after the company's US arm announced the launch of Olanzapine single-dose vial.

Aurobindo Pharma nears all-time high, up 30% in 4 months; more upside left?

Aurobindo Pharma stock hit a 52-week high at ₹1,585, and quoted close to its record high of ₹1,592 hit in September 2024. HDFC Securities maintains 'Add' rating on the stock.

Dr Reddys gains over 4%; hits 52-week high on near 3X jump in volume

Dr Reddys Laboratories stock hit a fresh 52-week high of ₹1,410 in Monday's intra-day trade, backed by strong surge in trading volume.

Nifty Pharma extends rally, up 2%; Piramal Pharma, Laurus gain up to 10%

Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.

Aurobindo Pharma stock jumps 2% after US FTC approves Lannett acquisition

Aurobindo Pharma received necessary approval from the US Federal Trade Commission (FTC) for the acquisition of the Lannett business.

New launches, India business growth key triggers for Zydus Lifesciences

Strong domestic growth, an expanding specialty portfolio, acquisitions and a robust product pipeline are expected to support Zydus Lifesciences' performance in FY27

Cipla shares jump 5% after Q4 results; records highest-ever yearly revenue

Cipla reported total income from operations of ₹6,541 crore, down 2.8 per cent year-on-year (Y-o-Y) from ₹6,730 crore in the year-ago period

Pharma, healthcare funds are in recovery mode. Should you enter them now?

Hold existing investments if you have a long horizon; book partial profits if exposure exceeds 10 per cent

Cipla Q4 preview: Profit may plunge on weak US sales; check estimates here

Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period